HRP20070146B1 - Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze - Google Patents

Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze

Info

Publication number
HRP20070146B1
HRP20070146B1 HRP20070146AA HRP20070146A HRP20070146B1 HR P20070146 B1 HRP20070146 B1 HR P20070146B1 HR P20070146A A HRP20070146A A HR P20070146AA HR P20070146 A HRP20070146 A HR P20070146A HR P20070146 B1 HRP20070146 B1 HR P20070146B1
Authority
HR
Croatia
Prior art keywords
novel
bcr
inhibitors
abl kinase
aminopyrimidine derivatives
Prior art date
Application number
HRP20070146AA
Other languages
English (en)
Inventor
Amala Kishan Kompella
Bhujanga Rao Adibhatla Kali Satya
Sreenivas Rachakonda
Khadgapathi Podili
Nannapaneni Venkaiah Chowdary
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of HRP20070146A2 publication Critical patent/HRP20070146A2/hr
Publication of HRP20070146B1 publication Critical patent/HRP20070146B1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Predmetni izum odnosi se na nove intermedijere koji su korisni u pripravi novih derivata fenil aminopirimidina. Farmaceutski pripravci koji sadrže nove derivate fenil aminopirimidina i postupak za pripravu istih. Predmetni izum posebice se odnosi na nove derivate fenil aminopirimidina opće formule (I). Novi spojevi formule mogu se koristiti u terapiji kronične mijeloidne leukemije (KML). Budući da se IC; 191 vrijednost dotičnih molekula nalazi u rasponu od 0,1 do 10,0 nm, predmetni novi spojevi potencijalno su korisni u liječenju KML.
HRP20070146AA 2004-09-09 2007-04-06 Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze HRP20070146B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN908CH2004 2004-09-09
PCT/IN2005/000243 WO2006027795A1 (en) 2004-09-09 2005-07-19 Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase

Publications (2)

Publication Number Publication Date
HRP20070146A2 HRP20070146A2 (hr) 2007-08-31
HRP20070146B1 true HRP20070146B1 (hr) 2015-12-04

Family

ID=35395645

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20070146AA HRP20070146B1 (hr) 2004-09-09 2007-04-06 Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze

Country Status (26)

Country Link
US (2) US7910598B2 (hr)
EP (2) EP1786799B1 (hr)
JP (1) JP5184887B2 (hr)
KR (1) KR100948453B1 (hr)
CN (1) CN101068805B (hr)
AP (1) AP2470A (hr)
AU (1) AU2005281299B2 (hr)
BR (1) BRPI0515081B8 (hr)
CA (1) CA2591321C (hr)
CY (1) CY1113617T1 (hr)
DK (1) DK1786799T3 (hr)
EA (1) EA013328B1 (hr)
ES (1) ES2390227T3 (hr)
HK (1) HK1110588A1 (hr)
HR (1) HRP20070146B1 (hr)
IL (1) IL181811A (hr)
MA (1) MA28922B1 (hr)
MX (1) MX2007002819A (hr)
NO (1) NO337598B1 (hr)
NZ (1) NZ554361A (hr)
PL (1) PL1786799T3 (hr)
PT (1) PT1786799E (hr)
SI (1) SI1786799T1 (hr)
UA (1) UA94570C2 (hr)
WO (1) WO2006027795A1 (hr)
ZA (2) ZA200701942B (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
US20110190328A1 (en) * 2004-09-09 2011-08-04 Natco Pharma Limited Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
SI1786799T1 (sl) 2004-09-09 2012-12-31 Natco Pharma Limited Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US8466180B2 (en) * 2006-09-11 2013-06-18 Syngenta Crop Protection Llc Insecticidal compounds
CA2668190A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
MY148851A (en) * 2006-12-14 2013-06-14 Bayer Ip Gmbh Dihydropyridine derivatives as useful as protein kinase inhibitors
US8268850B2 (en) * 2007-05-04 2012-09-18 Irm Llc Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors
CN101720322A (zh) * 2007-05-04 2010-06-02 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的化合物和组合物
CN101784530A (zh) 2007-08-22 2010-07-21 Irm责任有限公司 作为激酶抑制剂的5-(4-(卤代烷氧基)苯基)嘧啶-2-胺化合物和组合物
ES2368876T3 (es) 2007-08-22 2011-11-23 Irm Llc Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
JP2011513380A (ja) * 2008-03-04 2011-04-28 ナトコ ファーマ リミテッド フェニルアミノピリミジン誘導体の結晶型
WO2012004801A1 (en) * 2010-07-07 2012-01-12 Hetero Research Foundation Process for imatinib mesylate
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
ES2761332T3 (es) 2011-09-01 2020-05-19 Novartis Ag Compuestos y composiciones como inhibidores de la cinasa c-kit
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
ES2637829T3 (es) * 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
PT3389633T (pt) 2015-12-18 2021-08-05 Natco Pharma Ltd Composições farmacêuticas compreendendo derivados de fenilaminopirimidina
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US11767319B2 (en) 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
TW202237097A (zh) 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法
CN113125689B (zh) * 2021-03-29 2022-02-22 创芯国际生物科技(广州)有限公司 一种新型mtt细胞活力检测试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015164A1 (en) * 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
WO2004029038A1 (en) * 2002-09-27 2004-04-08 Novartis Ag Novel pyrimidineamide derivatives and the use thereof
WO2004110452A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (hr) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PL179417B1 (en) 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
ATE325113T1 (de) 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
MXPA01000895A (es) * 1998-08-04 2002-08-20 Astrazeneca Ab Derivados de amida utiles como inhibidores de la produccion de citocinas.
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
AU2003246100A1 (en) * 2002-06-28 2004-01-19 Nippon Shinyaku Co., Ltd. Amide derivative
AU2003242988A1 (en) * 2003-06-06 2005-01-04 Adibhatla Kali Sathya Bhujanga Rao Process for the preparation of the anti-cancer drug imatinib and its analogues
SI1786799T1 (sl) 2004-09-09 2012-12-31 Natco Pharma Limited Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze
CA2668190A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015164A1 (en) * 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
WO2004029038A1 (en) * 2002-09-27 2004-04-08 Novartis Ag Novel pyrimidineamide derivatives and the use thereof
WO2004110452A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M. OGATA, ET AL.: "Synthesis and antiviral activity of sulphonamidobenzophenone oximes and sulphonamidobenzamides", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 29., no. 03., 1 March 1986 (1986-03-01), US, pages 417 - 423., XP002096176, ISSN: 0022-2623, DOI: 10.1021/jm00153a018 *
SCHINDLER T,ET AL: "Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase.", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 289, no. 5486, 1 January 2000 (2000-01-01), US, pages 1938 - 1942, XP002229886, ISSN: 0036-8075, DOI: 10.1126/science.289.5486.1938 *
ZIMMERMANN J ET AL: "Potent and selective inhibitors of the ABL-kinase: Phenylaminopyrimidine (PAP) derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 7, no. 2, 1 January 1997 (1997-01-01), AMSTERDAM, NL, pages 187 - 192, XP002214446, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(96)00601-4 *

Also Published As

Publication number Publication date
CA2591321A1 (en) 2006-03-16
MA28922B1 (fr) 2007-10-01
ZA200703123B (en) 2008-10-29
US7910598B2 (en) 2011-03-22
ES2390227T3 (es) 2012-11-07
AU2005281299A1 (en) 2006-03-16
IL181811A0 (en) 2007-07-04
BRPI0515081B8 (pt) 2021-05-25
AU2005281299B2 (en) 2012-03-15
AP2470A (en) 2012-09-17
NZ554361A (en) 2009-03-31
PT1786799E (pt) 2012-09-18
CN101068805A (zh) 2007-11-07
EP1786799A1 (en) 2007-05-23
CA2591321C (en) 2013-09-24
ZA200701942B (en) 2008-10-29
EA013328B1 (ru) 2010-04-30
BRPI0515081B1 (pt) 2021-05-04
SI1786799T1 (sl) 2012-12-31
BRPI0515081A (pt) 2008-07-08
JP2008512448A (ja) 2008-04-24
EP2295424A1 (en) 2011-03-16
CN101068805B (zh) 2013-04-03
CY1113617T1 (el) 2016-06-22
HRP20070146A2 (hr) 2007-08-31
EA200700601A1 (ru) 2008-02-28
MX2007002819A (es) 2007-08-14
PL1786799T3 (pl) 2012-12-31
US8183253B2 (en) 2012-05-22
AP2007003944A0 (en) 2007-04-30
IL181811A (en) 2013-07-31
UA94570C2 (en) 2011-05-25
KR100948453B1 (ko) 2010-03-17
WO2006027795A1 (en) 2006-03-16
HK1110588A1 (en) 2008-07-18
EP2295424B1 (en) 2015-10-14
KR20070106681A (ko) 2007-11-05
US20080306100A1 (en) 2008-12-11
DK1786799T3 (da) 2012-10-01
NO20071521L (no) 2007-06-11
EP1786799B1 (en) 2012-07-04
JP5184887B2 (ja) 2013-04-17
US20070232633A1 (en) 2007-10-04
NO337598B1 (no) 2016-05-09

Similar Documents

Publication Publication Date Title
HRP20070146B1 (hr) Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze
HRP20070076A2 (hr) Derivati pirimidina
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
HRP20151410T1 (hr) Derivati pikolinamida kao inhibitori kinaze
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
EA200870282A1 (ru) Производные амина
HRP20050710A2 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MY155695A (en) Quinoxalinedione derivatives
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200626593A (en) Novel compounds
MY157116A (en) Novel seh inhibitors and their use
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
ATE481972T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
GB0514811D0 (en) Compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190704

Year of fee payment: 15

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200703

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210623

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20220719